Latest News

Dow Jones Newswires: Novartis hemoglobinuria trial meets two primary endpoints

Novartis AG
NOVN,
+0.47%

NVS,
+2.05%

said Monday that a study on a drug to treat adult paroxysmal nocturnal hemoglobinuria, a red blood cell condition, has met its two primary endpoints.

The trial studied a drug named Iptacopan and established its superiority to a previously used treatment in helping patients with debilitating anemia who would normally undergo blood transfusions, according to the company.

“Iptacopan was well tolerated with a favorable safety profile consistent with previously reported data,” Novartis said.

Write to Cecilia Butini at cecilia.butini@wsj.com

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in:Latest News